DURHAM, N.C., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, will host a conference call on Thursday, August 10, 2017 at 4:30 p.m. EDT to discuss second quarter 2017 financial results and recent operational highlights. A question-and-answer session will follow Dova's remarks.
To participate on the live call, please dial 866-550-8145 (domestic) or +1-430-775-1344 (international) and provide the conference ID 64454018 five to 10 minutes before the start of the call.
A live audio webcast of the call will also be available via the "Investor Relations" page of the Dova website, www.dova.com. Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.
About Dova Pharmaceuticals, Inc.
Dova is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. The company’s lead drug candidate, avatrombopag, recently completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease undergoing planned medical procedures.
Source:Dova Pharmaceuticals, Inc.